The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Delphinus: daratumumab in R/R T-ALL & T-LBL
Ajay Vora, MD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, discusses the results of Delphinus (NCT03384654), a Phase I/II study investigating the impact of the addition of daratumumab to induction and consolidation therapy in pediatric and young adult patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL). Whilst the study did not meet its primary endpoint, showing that there was no improvement in remission rates with daratumumab, it reported that the addition of daratumumab to consolidation therapy led to a better depth of response, overall response rate (ORR), and event-free survival (EFS) rate. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
